IL6 and cardiovascular disorder: Risk-based screening protocols for cardiovascular disease and metabolic dysfunction should be considered in this population, potentially guided by inflammatory and endothelial biomarkers (e.g., hs-CRP, sVCAM-1, IL-6) [27].